MX2016010519A - Moleculas para administracion a celulas cancerosas mutantes ros1. - Google Patents

Moleculas para administracion a celulas cancerosas mutantes ros1.

Info

Publication number
MX2016010519A
MX2016010519A MX2016010519A MX2016010519A MX2016010519A MX 2016010519 A MX2016010519 A MX 2016010519A MX 2016010519 A MX2016010519 A MX 2016010519A MX 2016010519 A MX2016010519 A MX 2016010519A MX 2016010519 A MX2016010519 A MX 2016010519A
Authority
MX
Mexico
Prior art keywords
ros1
administration
molecules
cancer cells
mutant cancer
Prior art date
Application number
MX2016010519A
Other languages
English (en)
Other versions
MX373042B (es
Inventor
Lim Jonathan
Ardina Elena
Menichincheri Maria
Original Assignee
Ignyta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ignyta Inc filed Critical Ignyta Inc
Publication of MX2016010519A publication Critical patent/MX2016010519A/es
Publication of MX373042B publication Critical patent/MX373042B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se exponen derivados de indazol sustituido de la fórmula (I) o la fórmula 2. (I) y sales farmacéuticamente aceptables de los mismos, como se definen en la especificación, un proceso para su preparación y composiciones farmacéuticas que los comprenden; los compuestos de la invención pueden ser útiles en terapia en el tratamiento de enfermedades asociadas con una actividad desregulada de la proteína cinasa, como el cáncer.
MX2016010519A 2014-02-20 2015-02-19 Moleculas para administracion a celulas cancerosas mutantes ros1. MX373042B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461942287P 2014-02-20 2014-02-20
US201462052994P 2014-09-19 2014-09-19
US201462055450P 2014-09-25 2014-09-25
US201462069999P 2014-10-29 2014-10-29
PCT/EP2015/053544 WO2015124697A1 (en) 2014-02-20 2015-02-19 Compounds for treating patients with ros1 mutant cancer cells

Publications (2)

Publication Number Publication Date
MX2016010519A true MX2016010519A (es) 2016-11-16
MX373042B MX373042B (es) 2020-06-19

Family

ID=52544499

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016010519A MX373042B (es) 2014-02-20 2015-02-19 Moleculas para administracion a celulas cancerosas mutantes ros1.

Country Status (20)

Country Link
US (4) US10231965B2 (es)
EP (2) EP3834827A1 (es)
JP (1) JP6636933B2 (es)
KR (2) KR20160117611A (es)
CN (1) CN106029073A (es)
AU (1) AU2015220832B2 (es)
BR (1) BR112016015818A2 (es)
CA (1) CA2933623C (es)
CL (1) CL2016001507A1 (es)
EA (1) EA033457B1 (es)
ES (1) ES2856231T3 (es)
IL (1) IL246544B (es)
MX (1) MX373042B (es)
NL (1) NL301111I2 (es)
PH (1) PH12016501394A1 (es)
PL (1) PL3107541T3 (es)
SG (1) SG11201605816TA (es)
TW (1) TWI672141B (es)
UA (1) UA118773C2 (es)
WO (1) WO2015124697A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2350075T3 (da) 2008-09-22 2014-05-26 Array Biopharma Inc Substituerede imidazo[1,2b]pyridazinforbindelser som trk-kinase-inhibitorer
PT3106463T (pt) 2008-10-22 2018-05-18 Array Biopharma Inc Compostos de pirazolo[1,5-]pirimidina substituídos como inibidores de cinase trk
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
RU2735545C2 (ru) 2010-05-20 2020-11-03 Эррэй Биофарма Инк. Макроциклические соединения в качестве ингибиторов киназы trk
HUE042591T2 (hu) 2013-02-19 2019-07-29 Ono Pharmaceutical Co TRK-gátló vegyület
TWI672141B (zh) 2014-02-20 2019-09-21 美商醫科泰生技 投予ｒｏｓ１突變癌細胞之分子
EP3218380B1 (en) 2014-11-16 2021-03-17 Array Biopharma, Inc. Preparation of a crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
CN107207471B (zh) 2014-12-02 2020-06-26 伊尼塔公司 用于治疗神经母细胞瘤的组合
EP3227686A4 (en) * 2014-12-03 2018-08-29 Ignyta, Inc. Multiplexed immunohistochemistry assays for diagnosis and treatment of cancer
PE20180329A1 (es) 2015-06-01 2018-02-13 Loxo Oncology Inc Metodos para diagnosticar y tratar el cancer
PT3322706T (pt) 2015-07-16 2021-03-08 Array Biopharma Inc Compostos de pirazolo[1,5-a]piridina substituídos como inibidores da quinase do ret
TN2019000271A1 (en) 2015-10-26 2021-01-07 Univ Colorado Regents Point mutations in trk inhibitor-resistant cancer and methods relating to the same
JP7061068B2 (ja) * 2015-12-18 2022-04-27 イグナイタ インコーポレイテッド 癌治療のための併用薬
TN2019000332A1 (en) 2016-04-04 2021-05-07 Loxo Oncology Inc Methods of treating pediatric cancers
IL304018A (en) 2016-04-04 2023-08-01 Loxo Oncology Inc Liquid formulations of (S)-N-(5-((R)-2-(5,2-difluorophenyl)-pyrrolidine-1-yl)-pyrazolo[5,1-A]pyrimidin-3-yl)-3 -hydroxypyrrolidine-1-carboxamide
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
ES2952056T3 (es) 2016-05-18 2023-10-26 Loxo Oncology Inc Preparación de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
PL3464276T3 (pl) 2016-05-24 2022-04-04 Nerviano Medical Sciences S.R.L. Nowa postać krystaliczna n-[5-(3,5-difluoro-benzylo)-1h-indazol-3-ilo)-4-(4-metylopiperazyn-1-ylo)-2-tetrahydropiran-4-yloamino)-benzamidu
US20190185567A1 (en) * 2016-08-01 2019-06-20 Ignyta, Inc. Combinations for the treatment of cancer
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JP6888101B2 (ja) 2017-01-18 2021-06-16 アレイ バイオファーマ インコーポレイテッド ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピラジン化合物
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
CN121401264A (zh) * 2017-07-19 2026-01-27 伊尼塔公司 包括恩曲替尼的药物组合物
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
WO2019077506A1 (en) * 2017-10-17 2019-04-25 Ignyta, Inc. PHARMACEUTICAL COMPOSITIONS AND SOLID GALENIC FORMS
US20190247398A1 (en) 2017-10-26 2019-08-15 Array Biopharma Inc. Formulations of a macrocyclic trk kinase inhibitor
WO2019143977A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
WO2019143991A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS
JP6997876B2 (ja) 2018-01-18 2022-02-04 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての置換ピラゾリル［４，３－ｃ］ピリジン化合物
US20210023086A1 (en) 2018-03-29 2021-01-28 Loxo Oncology, Inc. Treatment of trk-associated cancers
JP7286755B2 (ja) 2018-07-31 2023-06-05 ロクソ オンコロジー， インコーポレイテッド （ｓ）－５－アミノ－３－（４－（（５－フルオロ－２－メトキシベンズアミド）メチル）フェニル）－１－（１，１，１－トリフルオロプロパン－２－イル）－１ｈ－ピラゾール－４－カルボキサミドの噴霧乾燥分散体および製剤
CA3111984A1 (en) 2018-09-10 2020-03-19 Array Biopharma Inc. Fused heterocyclic compounds as ret kinase inhibitors
JP2022515198A (ja) 2018-12-19 2022-02-17 アレイ バイオファーマ インコーポレイテッド ＦＧＦＲチロシンキナーゼの阻害剤としての置換ピラゾロ［１，５－ａ］ピリジン化合物
CN113474337A (zh) 2018-12-19 2021-10-01 奥瑞生物药品公司 作为fgfr抑制剂用于治疗癌症的7-((3，5-二甲氧基苯基)氨基)喹喔啉衍生物

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
JPS6041489A (ja) 1983-08-12 1985-03-05 Kyowa Hakko Kogyo Co Ltd 新規生理活性物質ｋ―２５２
WO1999043302A1 (en) 1998-02-27 1999-09-02 Watson Pharmaceuticals, Inc. Stabilizing composition for pharmaceutical dosage forms
JP2002275068A (ja) 2001-03-16 2002-09-25 Kyowa Hakko Kogyo Co Ltd アポトーシス誘導剤
ES2275021T3 (es) 2001-09-27 2007-06-01 Smithkline Beecham Corporation Derivados de azoxoindol como inhibidores de trk proteina quinasa para el tratamiento de cancer y dolor cronico.
WO2003051847A1 (en) 2001-12-19 2003-06-26 Smithkline Beecham P.L.C. (1-h-indazol-3-yl) -amide derivatives as gsk-3 inhibitors
FR2836915B1 (fr) 2002-03-11 2008-01-11 Aventis Pharma Sa Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
AU2003251875A1 (en) 2002-07-15 2004-02-02 Combinatorx, Incorporated Combination therapy for the treatment of neoplasms
WO2004022544A1 (fr) 2002-09-05 2004-03-18 Aventis Pharma S.A. Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant
MXPA05005554A (es) 2002-12-12 2005-07-26 Aventis Pharma Sa Derivados de aminoindazol y su utilizacion como inhibidores de quinasas.
TW200423938A (en) 2003-02-21 2004-11-16 Wyeth Corp 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury
GEP20084341B (en) 2003-02-26 2008-03-25 Sugen Inc Aminoheteroaryl compounds as protein kinase inhibitors
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
EP1626950A4 (en) 2003-05-23 2007-05-23 Transform Pharmaceuticals Inc SERTRALINZUSAMMENSETZUNGEN
EP2392565B1 (en) 2003-09-26 2014-03-19 Exelixis, Inc. c-Met modulators and methods of use
JP2007508801A (ja) 2003-10-24 2007-04-12 エスバテック・アーゲー 受容体チロシンキナーゼ阻害剤の同定および／または確認のための方法
FR2871158A1 (fr) 2004-06-04 2005-12-09 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
CN101111483B (zh) 2005-01-27 2011-12-14 协和发酵麒麟株式会社 Igf-1r抑制剂
WO2006111035A1 (en) 2005-04-21 2006-10-26 Oncalis Ag Method for the identification of possibly harmful receptor tyrosine kinase (rtk) mutations and of inhibitors or medication directed against rtk mutantstitle
BRPI0610184A2 (pt) 2005-05-16 2012-09-25 Astrazeneca Ab composto, sal farmaceuticamente aceitável de um composto, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, métodos para a inibição da atividade de trk, para o tratamento ou profilaxia de cáncer e para a produção de um efeito anti-proliferativo em um animal de sanque quente, e, composição farmacêutica
BRPI0614809A2 (pt) 2005-08-09 2011-04-12 Johannes Gutenberg Universitaet Mainz sensibilização de cánceres de pulmão resistentes a fármaco a inibidores de proteìna cinase
JP2009520825A (ja) 2005-12-20 2009-05-28 武田薬品工業株式会社 グルコキナーゼ活性剤
DE102006030479A1 (de) 2006-07-01 2008-03-20 Merck Patent Gmbh Indazolderivate
WO2008005956A2 (en) 2006-07-07 2008-01-10 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7790756B2 (en) 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
KR101364277B1 (ko) 2006-12-08 2014-02-21 아이알엠 엘엘씨 단백질 키나제 억제제로서의 화합물
BRPI0720059A2 (pt) 2006-12-11 2013-12-17 Irm Llc Compostos e composições como inibidores de cinase
ES2509820T3 (es) 2006-12-20 2014-10-20 Nerviano Medical Sciences S.R.L. Derivados de indazol como inhibidores de la cinasa para el tratamiento del cáncer
JP2010532758A (ja) 2007-07-06 2010-10-14 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド 組み合わせ抗癌療法
EA018503B1 (ru) 2007-07-20 2013-08-30 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Замещенные производные индазола, активные как ингибиторы киназы
ES2635131T3 (es) 2007-08-29 2017-10-02 Methylgene Inc. Inhibidores de la actividad de la proteína tirosina cinasa
PT3106463T (pt) 2008-10-22 2018-05-18 Array Biopharma Inc Compostos de pirazolo[1,5-]pirimidina substituídos como inibidores de cinase trk
CN102924479A (zh) 2011-08-09 2013-02-13 山东鲁北药业有限公司 一种星孢菌素类衍生物的半合成方法
CN104364391A (zh) 2012-02-08 2015-02-18 因赛特遗传学公司 用于诊断和治疗癌症的涉及ros1融合的方法和组合物
LT2822953T (lt) 2012-03-06 2017-04-10 Pfizer Inc. Makrocikliniai dariniai, skirti proliferacinių ligų gydymui
JP6231556B2 (ja) 2012-05-23 2017-11-15 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ Ｎ−［５−（３，５−ジフルオロ−ベンジル）−１ｈ−インダゾール−３−イル］−４−（４−メチル−ピペラジン−１−イル）−２−（テトラヒドロ−ピラン−４−イルアミノ）−ベンズアミドの調製方法
CA2885944A1 (en) 2012-09-28 2014-05-08 Oncoethix Sa Pharmaceutical formulation containing thienotriazolodiazepine compounds
WO2014093750A1 (en) 2012-12-14 2014-06-19 Glaxosmithkline Llc Method of administration and treatment
DE102013012850B4 (de) * 2013-08-02 2025-09-11 Sew-Eurodrive Gmbh & Co Kg Elektromotor mit Rotorwelle und Gehäuseteil
TWI672141B (zh) 2014-02-20 2019-09-21 美商醫科泰生技 投予ｒｏｓ１突變癌細胞之分子
LT3154959T (lt) 2014-05-15 2019-09-25 Array Biopharma, Inc. 1-((3s,4r)-4-(3-fluorfenil)-1-(2-metoksietil)pirolidin-3-il)-3-(4-metil-3-(2-metilpirimidin-5-il)-1-fenil-1h-pirazol-5-il)karbamidas kaip trka kinazės inhibitorius
US20170114415A1 (en) * 2014-05-30 2017-04-27 The Regents Of The University Of Colorado, A Body Corporate Activating ntrk1 gene fusions predictive of kinase inhibitor therapy
RU2017100921A (ru) 2014-06-13 2018-07-13 Онкоэтикс Гмбх Способ лечения немелкоклеточного рака легких и/или мелкоклеточного рака легких с применением соединений тиенотриазолодиазепина
CN107207471B (zh) 2014-12-02 2020-06-26 伊尼塔公司 用于治疗神经母细胞瘤的组合
EP3227686A4 (en) 2014-12-03 2018-08-29 Ignyta, Inc. Multiplexed immunohistochemistry assays for diagnosis and treatment of cancer
WO2016196141A1 (en) 2015-05-29 2016-12-08 Ignyta, Inc. Compositions and methods for treating patients with rtk mutant cells
PE20180329A1 (es) 2015-06-01 2018-02-13 Loxo Oncology Inc Metodos para diagnosticar y tratar el cancer
TN2019000271A1 (en) 2015-10-26 2021-01-07 Univ Colorado Regents Point mutations in trk inhibitor-resistant cancer and methods relating to the same
JP7061068B2 (ja) 2015-12-18 2022-04-27 イグナイタ インコーポレイテッド 癌治療のための併用薬
CN121401264A (zh) 2017-07-19 2026-01-27 伊尼塔公司 包括恩曲替尼的药物组合物
WO2019077506A1 (en) 2017-10-17 2019-04-25 Ignyta, Inc. PHARMACEUTICAL COMPOSITIONS AND SOLID GALENIC FORMS

Also Published As

Publication number Publication date
NL301111I2 (nl) 2021-09-27
ES2856231T3 (es) 2021-09-27
CA2933623C (en) 2022-05-17
TW201613593A (en) 2016-04-16
EP3107541B1 (en) 2020-12-23
JP2017506255A (ja) 2017-03-02
US10231965B2 (en) 2019-03-19
KR20220165787A (ko) 2022-12-15
AU2015220832A2 (en) 2016-09-08
UA118773C2 (uk) 2019-03-11
US20170007599A1 (en) 2017-01-12
US20150283132A1 (en) 2015-10-08
MX373042B (es) 2020-06-19
EA201691151A1 (ru) 2017-01-30
PL3107541T3 (pl) 2021-09-20
IL246544A0 (en) 2016-08-31
US20190282564A1 (en) 2019-09-19
CA2933623A1 (en) 2015-08-27
PH12016501394A1 (en) 2017-02-20
KR102634514B1 (ko) 2024-02-07
AU2015220832B2 (en) 2020-02-27
EA033457B1 (ru) 2019-10-31
US10561651B2 (en) 2020-02-18
WO2015124697A1 (en) 2015-08-27
EP3834827A1 (en) 2021-06-16
US10682348B2 (en) 2020-06-16
US20180333412A1 (en) 2018-11-22
CL2016001507A1 (es) 2017-02-10
EP3107541A1 (en) 2016-12-28
KR20160117611A (ko) 2016-10-10
CN106029073A (zh) 2016-10-12
AU2015220832A1 (en) 2016-09-08
JP6636933B2 (ja) 2020-01-29
BR112016015818A2 (pt) 2017-08-08
IL246544B (en) 2019-12-31
SG11201605816TA (en) 2016-08-30
TWI672141B (zh) 2019-09-21
NL301111I1 (es) 2021-06-23
NZ722405A (en) 2021-03-26

Similar Documents

Publication Publication Date Title
MX2016010519A (es) Moleculas para administracion a celulas cancerosas mutantes ros1.
CO2017000912A2 (es) Derivados de 2 -h indazol como inhibidores de kinasas dependientes de ciclinas (cdk) y usos terapeuticos de los mismos
CY1122566T1 (el) Παραγωγο 6,7,8,9-tetpaϋδpo-3h-πυραζολo[4,3-f] ισοκινολινης χρησιμο στη θεραπευτικη αντιμετωπιση του καρκινου
CY1122730T1 (el) 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων
MX2017016344A (es) Compuestos de benzoxacepina oxazolidinona y metodos de uso.
MX379155B (es) Compuestos que inhiben la proteína mcl-1.
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
ECSP109934A (es) Compuesto - 946
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
DK2324008T3 (da) Diarylpyrazol som protein kinase inhibitorer
DOP2010000012A (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k
CO2019009722A2 (es) Dendrímeros terapéuticos
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
UY32190A (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibdores de quinasas dependientes de ciclina (cdk), produccion y uso de los mismos como productos medicinales
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
MX2017001603A (es) Derivados de piperazina como moduladores de los receptores x del higado.
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.
MX368735B (es) (r)-pirlindol y sus sales farmaceuticamente aceptables para uso en medicina.
PH12020500436A1 (en) Aromatic derivative, preparation method for same, and medical applications thereof
EA201891027A1 (ru) Фармацевтическая композиция, содержащая производные индола, способ ее получения и применение
AR105921A1 (es) Compuestos terapéuticos para el dolor y síntesis de estos
CU20100005A7 (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
CU20100003A7 (es) Derivados trisustituídas de pirimidina para el tratamiento de enfermedades proliferativas

Legal Events

Date Code Title Description
FG Grant or registration